Loading clinical trials...

Treatment of Moderate FMR During AVR | Clinical Trials | Clareo Health

UNKNOWN

Treatment of Moderate FMR During AVR

Surgical Treatment of Aortic Valve Disease With Moderate Functional Mitral Regurgitation

NCT05566340•Fuwai Yunnan Cardiovascular Hospital

Summary

Debates exist on the treatment of moderate functional mitral regurgitation (FMR) in patients undergoing aortic valve replacement (AVR) for aortic valve disease. This study aims to evaluate the left ventricular function, which was evaluated through global longitudinal strain, after isolated AVR and AVR + mitral valve repair (MVr) in this group of patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients who received AVR (with or without concomitant MVr) from two center (Fuwai Yunnan Cardiovascular Hospital and Fuwai Hospital, Chinese Academy of Medical Sciences).
•2. Age more than 18 years.

Exclusion Criteria

•1. Those with a history of rheumatic valvular disease or infective endocarditis.
•2. Primary mitral valve lesions.
•3. Patients receiving mitral valve replacement.
•4. Patient who refuse to participate in this study, or cannot complete 6-month follow-up after surgery.
•5. Age \< 18 years.

Key Dates

Start Date

October 1, 2022

Primary Completion Date

October 1, 2023

Completion Date

December 1, 2023

Last Updated

October 4, 2022

Enrollment

154

ESTIMATED participants

Conditions

Functional Mitral Regurgitation

Interventions

mitral valve repair

PROCEDURE

Contacts

Xieraili Tiemuerniyazi

CONTACT

+86-18814115887 tiemuernyz@mail2.sysu.edu.cn

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

NCT03142152

Functional Mitral RegurgitationHeart Failure+4 more

View study

RECRUITING

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)

NCT06911099

Atrial Functional Mitral RegurgitationMitral Insufficiency

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 4, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Moderate FMR During AVR

Inclusion Criteria

Exclusion Criteria

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)

The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation

Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)

An Initial Evaluation of the Carillon Mitral Contour System for Treatment of Atrial Function Mitral Regurgitation